Cellectis receives arbitral decision in Servier licensing dispute

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. GPRK
6. SCHW
7. TRV
8. TFC
9. TECHM:IN
10. NVDA

Go back to Cellectis receives arbitral decision in Servier licensing dispute

Cellectis Announces Arbitral Decision in Dispute with Servier

December 15, 2025 4:51 PM EST

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the Company) (Euronext Growth: ALCLS NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces that the Arbitral Tribunal has issued its decision in the arbitration proceedings against Les Laboratoires Servier and Institut de Recherches Internationales Servier IRIS SARL (Servier), relating to the License, Development and Commercialization Agreement entered into between Servier and Cellectis on March 6, 2019, as... More